Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Summit Therapeutics Inc (SMMT) Price & Performance

CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.11, up 0.49% on the day but reflecting a bearish technical signal with moving averages indicating strong selling pressure. The ETF has experienced significant volatility and value erosion, with news highlighting a 67% year-to-date loss as of June 2026 due to the daily-reset leverage structure amplifying Coinbase's price swings. Key financial ratios are not applicable as this is a leveraged ETF tracking another security.

Outlook remains highly speculative and risky due to the ETF's daily leverage, which can lead to rapid losses in volatile markets. Investment opportunity is limited to short-term traders betting on Coinbase rallies, but risks include volatility decay, tracking error, and dependence on Coinbase performance. Long-term holding is discouraged by the structure's inherent erosion.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.